Efgartigimod alfa

VYVGART HYTRULO is indicated for the treatment of adult patients with: generalized myasthenia gravis (gMG) chronic inflammatory demyelinating polyneuropathy (CIDP) VYVGART HYTRULO is a combination of efgartigimod alfa

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗

Drug facts

Used for: VYVGART HYTRULO is indicated for the treatment of adult patients with: generalized myasthenia gravis (gMG) chronic inflammatory demyelinating polyneuropathy (CIDP) VYVGART HYTRULO is a combination of efgartigimod alfa
Do not take if: VYVGART is contraindicated in patients with serious hypersensitivity to efgartigimod alfa products or to any of the excipients of VYVGART.
Reactions have included anaphylaxis and hypotension leading to syncope.

What it is used for

VYVGART is indicated for the treatment of adult patients with generalized myasthenia gravis (gMG).

Side effects, and when to stop

The following clinically significant adverse reactions are described elsewhere in the labeling:

Infections
Hypersensitivity Reactions
Infusion-Related Reactions

Who should not take it

VYVGART is contraindicated in patients with serious hypersensitivity to efgartigimod alfa products or to any of the excipients of VYVGART. Reactions have included anaphylaxis and hypotension leading to syncope.

Storing it

Store VYVGART vials refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light until time of use. Do not freeze. Do not shake.

Refer to Dosage and Administration for information on stability and storage of the diluted solutions of VYVGART.

Cite this page

NLM: sofidex [Internet]. Daloreum; c2026. Efgartigimod alfa; [reviewed 2026 Aug 2; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/efgartigimod-alfa
APA 7th: sofidex. (2026, August 2). Efgartigimod alfa. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/efgartigimod-alfa
AMA 11th: Efgartigimod alfa. sofidex. Reviewed August 2, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/efgartigimod-alfa

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.